FDX1 and nonpapillary renal cell carcinoma: Second, since the datasets collected to analyze the role of FDX1 in ccRCC mainly consisted of pretreatment cohorts, future validation should consider datasets based on clinical trial studies, including chemotherapy and immunotherapy combination therapy.